GLPwatch
Papers (9189)
Page 74 of 154, ranked by citation count.
- Application of Af4-Multidetection to Liraglutide in Its Formulation: Preserving and Representing Native Aggregation.
- Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure.
- Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist.
- Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
- Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?
- Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes.
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
- Factors Associated With Semaglutide Initiation Among Adults With Obesity.
- Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
- Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
- Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.
- Liraglutide for the Treatment of Weight Regain After Bariatric Surgery: A Systematic Review and Meta-analysis.
- Hyperglycemia and adverse outcomes in acute coronary syndromes: is serum glucose the provocateur or innocent bystander?
- New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
- Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
- Glucagon like-peptide 1 receptor and the liver.
- 10-fold liraglutide overdose over 7 months resulted only in minor side-effects.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
- Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
- Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO<sup>2</sup> S-RWD).
- Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma.
- Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.
- Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model.
- Innovative chemical synthesis and conformational hints on the lipopeptide liraglutide.
- Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.
- Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c‑JUN signaling pathway.
- Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
- Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.
- Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
- Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.
- Up and down waves of glycemic control and lower-extremity amputation in diabetes.
- Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.
- Dipeptidyl peptidase-4 disturbs adipocyte differentiation via the negative regulation of the glucagon-like peptide-1/adiponectin-cathepsin K axis in mice under chronic stress conditions.
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
- Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
- Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.
- Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
- Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
- The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
- Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
- Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-β/PI3K/NF-κB signaling pathway.
- Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
- Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
- Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells.
- High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management.
- Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin.
- Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.
- Liraglutide-induced acute pancreatitis.
- An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits.
- Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials.
- Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.
- Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
- Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression.
- Enhanced Peptide Stability Against Protease Digestion Induced by Intrinsic Factor Binding of a Vitamin B12 Conjugate of Exendin-4.
- Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.
- The fetal origins of the metabolic syndrome: can we intervene?
- The GLP-1 receptor is expressed <i>in vivo</i> by human metastatic prostate cancer.
- Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity.